5005 MCCONNELL AVE, LOS ANGELES, CA
Announces First Quarter 2026 Results and Provides Corporate Update
Secures FDA Fast Track Designation for AP-SA02
Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
Annual Report to Security Holders
Other Events
Financial Results, Press Release
Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13D - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload